Massive layoffs at TevaGeneric drugmaker Teva has announced a massive 14,000 job cuts, representing 25% of its 59,000-strong work force, report Handelsblatt (p25), Sueddeutsche Zeitung (SZ) (p20), Frankfurter Allgemeine Zeitung (FAZ) (p23) and Die Welt (p9) on Friday (APMHE 56052).
Price moratorium faces constitutional courtGerman medium-sized pharma company InfectoPharm has filed a constitutional complaint with the federal constitutional court against the price moratorium for drugs effective in Germany since 2009, reported FAZ on Saturday (p23) (APMHE 55931).
Medigene enters cancer research cooperationGerman biotech Medigene has entered into a research collaboration with U.S.-based Rxi Pharmaceuticals, reported FAZ on Tuesday (p21).
BioNTech developing in MainzCancer vaccine developer BioNTech intends to further expand its facilities in Mainz, near Frankfurt, reported FAZ on Thursday (p40).
Pharmacists protest fee reductionsGerman pharmacists are horrified by a proposal to cut their fees by 1.3 billion euros, reported FAZ on Monday (p17) and Tuesday (p17).
Health insurers at risk of bankruptcyAbout a dozen statutory health insurers covering around 15 million people are at risk of bankruptcy in the coming years if healthcare financing is not reformed, warned chair of major German insurer Barmer Christoph Straub, FAZ reported on Thursday (p15).
Controversial U.S. guidelines for high blood pressureThe new U.S. guidelines defining hypertension as more than 130/80mmHg, after a previous limit of 140/90mmHg, are controversial, FAZ reported on Sunday (p21).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.